Compare AbCellera Biologics Inc (ABCL) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Williams-Sonoma, Inc. — how do they compare? AbCellera Biologics Inc trades at $10.24 (market cap $3.17B), while Williams-Sonoma, Inc. trades at $250.52 (market cap $28.87B). The key difference: Williams-Sonoma, Inc. is far larger — about 9.1× AbCellera Biologics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.24% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WSM | |
|---|---|---|
Market Cap | $3.17B | $28.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $10.36 | $251.81 |
52-Week Low | $2.78 | $168.64 |
Enterprise Value | $2.77B | $29.71B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
Williams-Sonoma (WSM) trades at $245.16, down 2.26% today, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 13.81% net income margin and 54.01% ROE, supported by recent earnings beats. Recent news highlights investor interest and a CEO stock sale, while cash flow trends show variability, with 2025 net cash flow at -$49 million.
Outlook remains positive with consistent earnings performance and a 'Moderate Buy' analyst consensus, though risks include consumer discretionary sector volatility and competitive pressures. The stock trades above the consensus price target of $231.10, suggesting limited near-term upside based on current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
